Officials effectively said a medicine can qualify for a special pricing arrangement if it met the criteria at a given point in time or some but not all of the criteria subsequently. …
Latest Video
New Stories
-
Disappointment for Australian innovation
July 19, 2019 - - Latest News -
Boehringer Ingelheim acquires new oncology platform
July 19, 2019 - - Latest News -
Gene and cell therapy boost Novartis second quarter
July 19, 2019 - - Latest News -
PhRMA: The risk of international reference pricing
July 18, 2019 - - Latest News -
J&J Innovation recognises undergraduates
July 18, 2019 - - Latest News -
Stakeholder meeting a little different to last time
July 18, 2019 - - Latest News -
Takeda: From CAR-T to off-the-shelf iCAR-T
July 18, 2019 - - Latest News